The coincidence of IgA nephropathy and Fabry disease

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Maixnerová, Dita ^a   Tesař, Vladimír ^a   Ryšavá, Romana ^a   Reiterová, Jana ^a   Poupětová, Helena ^b   Dvořáková, Lenka ^b   Goláň, Lubor ^a   Neprašová, Michaela ^a   Kidorová, Jana ^a   Merta, Miroslav ^a   Honsová, Eva ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Charles University in Prague and General University Hospital in Prague   (Czech Republic)

Author keywords

Alpha galactosidase A; Fabry disease; IgA nephropathy

Indexed keywords

ALPHA GALACTOSIDASE; CREATININE; DNA; PREDNISONE; RNA;

ADULT; ARTICLE; BLOOD TESTIS BARRIER; CASE REPORT; COMORBIDITY; CREATININE BLOOD LEVEL; DISEASE COURSE; DNA DETERMINATION; ELECTRON MICROSCOPY; ENZYME ACTIVITY; ENZYME REPLACEMENT; FABRY DISEASE; FAMILY ASSESSMENT; FEMALE; FEVER; GENETIC ANALYSIS; GLOMERULONEPHRITIS; HEART VENTRICLE HYPERTROPHY; HEMATURIA; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; NEUROPATHIC PAIN; PODOCYTE; RNA ANALYSIS;

ADULT; DIAGNOSIS, DIFFERENTIAL; FABRY DISEASE; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; MALE;

EID: 84872161580     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-6     Document Type: Article

References (35)

1. IgA nephropathy and Henoch-Schonlein Nephritis. Johnson JR, John Feehally J, Clin Nephrol 2003 24 319 329
2. IgA nephropathy in two adolescent sisters heterozygous for Fabry disease. Whybra C, Schwarting A, Kriegsmann J, Gal A, Mengel E, Kampmann C, Baehner F, Schaefer E, Beck M, Pediatr Nephrol 2006 21 1251 1256 10.1007/s00467-006-0176-5 16838183 (Pubitemid 44203450)
3. The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. Poupětová H, Ledvinová J, Berná L, Dvořáková L, Kožich V, Elleder M, J Inherit Metab Dis 2010 33 387 396 10.1007/s10545-010-9093-7 20490927
4. A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Merta M, Reiterova J, Ledvinova J, Poupetová H, Dobrovolny R, Rysavá R, Maixnerová D, Bultas J, Motán J, Slivkova J, Sobotova D, Smrzova J, Tesar V, Nephrol Dial Transplant 2007 22 1 179 186 17040996 (Pubitemid 46050343)
5. Fabry disease: 45 novel mutations in the alpha-galactosidase A gene causing the classical phenotype. Shabbeer J, Yasuda M, Luca E, Desnick RJ, Mol Genet Metab 2002 76 1 23 30 10.1016/S1096-7192(02)00012-4 12175777
6. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM, Nephrol Dial Transplant 2002 17 1197 1203 10.1093/ndt/17.7.1197 12105241 (Pubitemid 34812063)
7. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. D'Amico G, Semin Nephrol 2004 24 179 196 10.1016/j.semnephrol. 2004.01.001 15156525 (Pubitemid 38685989)
8. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. Dobrovolny R, Dvořákova L, Ledvinová J, Magage S, Bultas J, Lubanda JC, Elleder M, Karetova D, Pavlíková M, Hřebíček M, J Mol Med 2005 83 647 654 10.1007/s00109-005-0656-2 15806320 (Pubitemid 41176074)
9. Fabry's disease associated with rheumatoid arthritis. Multisystemic crossroads. Martinez AN, Hernandez BFJ, Martin PG, An Med Interna 2003 20 28 30 12666306
10. High incidence of autoantibodies in Fabry disease patients. Martinez P, Aggio M, Rozenfeld P, J Inherit Metab Dis 2007 30 365 369 10.1007/s10545-007- 0513-2 17458709 (Pubitemid 46881683)
11. A case of Fabry's disease associated with lupus nephritis. Majima K, Ishizaki T, Inoue T, Hori Y, Egami J, Oohara A, Nishida H, Miyake Y, Matsumoto S, Kinoshita E, Nihon Jinzo Gakkai Shi 1992 34 1189 1194 1338214
12. Coexistence of Fabry's disease and systemic lupus erythematosus. Rahman P, Gladman DD, Wither J, Silver MD, Clin Exp Rheumatol 1998 16 475 478 9706432 (Pubitemid 28370863)
13. Kidney involvement in systemic lupus erythematosus and Fabry's disease. Rosenmann E, Kobrin I, Cohen T, Nephron 1983 34 180 184 10.1159/000183006 6410291 (Pubitemid 13096580)
14. Different phenotypic expression in relatives with fabry disease caused by a W226X mutation. Knol IE, Ausems MG, Lindhout D, et al. Am J Med Genet 1999 82 436 439 10.1002/(SICI)1096-8628(19990219)82:5<436::AID-AJMG14>3.0.CO;2-X 10069717 (Pubitemid 29096155)
15. The co-existence of Fabry and celiac diseases:a case report. Tumer L, Ezgu FS, Hasanoglu A, Dalgic B, Bakkaloglu SA, Memis L, Dursun A, Pediatr Nephrol 2004 19 679 681 10.1007/s00467-004-1462-8 15085421 (Pubitemid 38771742)
16. A case of Fabry's disease with granulomatous interstitial nephritis. Hiraizumi Y, Kanoh M, Shigematsu H, Yamashina M, Kondo T, Nippon Jinzo Gakkai Shi 1995 37 655 661 8583703
17. Novel frameshift mutation in a heterozygous woman with Fabry disease and end-stage renal failure. Van Loo A, Vanholder R, Madsen K, Praet M, Kint J, De Paepe A, Messiaen L, Lameire N, Hasholt L, Sorensen SA, Ringoir S, Am J Nephrol 1996 16 352 357 10.1159/000169023 8739292 (Pubitemid 26143588)
18. Coexistence of Fabry's disease and necrotizing and crescentic glomerulonephritis. Singh HK, Nickeleit V, Kriegsmann J, Harris AA, Jennette JC, Mihatsch MJ, Clin Nephrol 2001 55 73 79 11200872 (Pubitemid 32041786)
19. Fabry-like laminated myelin body associated with IgA nephropathy. Yoshida A, Morozumi K, Takeda A, Koyama K, Oikawa T, Nippon Jinzo Gakkai Shi 1994 36 1303 1307 7853764
20. Fabry nephropathy in a female with superposed IgA glomerulonephritis. Pisani A, Sessa A, Sabbatini M, Andreucci MV, Fusco C, Balletta M, Cianciaruso B, G Ital Nefrol 2005 22 385 389 16267800
21. Coincidental finding of Fabry's disease in a patient with IgA nephropathy. Kakita T, Nagatoya K, Mori T, NDT Plus 2010 3 443 446 10.1093/ndtplus/sfq108
22. Subclinical Fabry's disease occurring in the context of IgA nephropathy. Kawamura O, Sakuraba H, Itoh K, Suzuki Y, Doi M, Kuwabara H, Oshima S, Abe S, Warabi H, Yoshizawa N, Clin Nephrol 1997 47 71 75 9049452 (Pubitemid 27077736)
23. Hemizygous Fabry disease associated with IgA nephropathy: a case report. Shimohata H, Yoh K, Takada K, Tanaka H, Usui J, Hirayama K, Kobayashi M, Yamagata K, J Nephrol 2009 22 5 682 684 19810002
24. Genetic studies of IgA nephropathy: past, present, and future. Kiryluk K, Julian BA, Wyatt RJ, Scolari F, Zhang H, Novak J, Gharavi AG, Pediatr Nephrol 2010 25 11 2257 2268 10.1007/s00467-010-1500-7 20386929
25. Race/ethnicity and disease severity in IgA nephropathy. Hall YN, Fuentes EF, Chertow GM, Olson JL, BMC Nephrol 2004 5 10,2369
26. Interactions of human mesangial cells with IgA and IgA-containing circulating immune complexes. Novak J, Vu HL, Novak L, Julian BA, Mestecky J, Tomana M, Kidney Int 2002 62 465 475 10.1046/j.1523-1755.2002.00477.x 12110007 (Pubitemid 34779757)
27. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Novak J, Tomana M, Matousovic K, Brown R, Hall S, Novak L, Julian BA, Wyatt RJ, Mestecky J, Kidney Int 2005 67 504 513 10.1111/j.1523-1755.2005.67107.x 15673298 (Pubitemid 40139842)
28. For further infestigations in IgA nephropathy the approach from phenotype to genotype is welcome. Schena FP, Clin Exp Immunol 2002 127 399 401 10.1046/j.1365-2249.2002.01821.x 11966754 (Pubitemid 34437810)
29. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, Snyder HJ, Choi M, Hou P, Scolari F, Izzi C, Gigante M, Gesualdo L, Savoldi S, Amoroso A, Cusi D, Zamboli P, Julian BA, Novak J, Wyatt RJ, Mucha K, Perola M, Kristiansson K, Viktorin A, Magnusson PK, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Boland A, Metzger M, Thibaudin L, Wanner C, Jager KJ, Goto S, Maixnerova D, Karnib HH, Nagy J, Panzer U, Xie J, Chen N, Tesar V, Narita I, Berthoux F, Floege J, Stengel B, Zhang H, Lifton RP, Gharavi AG, PLoS Genet 2012 8 6 1002765 Epub 2012 Jun 21 10.1371/journal.pgen.1002765 22737082
30. Characterization of antibodies against ceramidetrihexoside and globoside. Hamers MN, Donker-Koopman WE, Coulon-Morelec MJ, Dupouey P, Tager JM, Immunochemistry 1978 15 6 353 358 10.1016/0161-5890(78)90130-X 700772 (Pubitemid 9099464)
31. Fabry's disease:α-galactosidase A deficiency. Desnick RJ, Sweeley CC, The Metabolic Basis of Inherited Disease NY: McGraw-Hill, Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, 5th 1983 906 944
32. The structure of nephritogenoside:a nephritogenic glycopeptide with α-N-glycosidic linkage. Shibata S, Takeda T, Natori Y, J Biol Chem 1988 263 12483 12485 3410849 (Pubitemid 19001545)
33. α-galactosidase A deficiency: Fabry Disease. Desnick RJ, Joannou YA, Eng CM, The Metabolic and Molecular Bases of Inherited Disease New York, USA: McGraw-Hill, Scriver CR, Beaudet AL, Sly WS, Valle D, 2001 3733 3774
34. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy:evidence for a better outcome with early treatment. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Störk S, Voelker W, Ertl G, Wanner C, Strotmann J, Circulation 2009 119 524 529 10.1161/CIRCULATIONAHA.108. 794529 19153271
35. Clinical benefit of enzyme replacement therapy in Fabry disease. Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C, Kidney Int 2006 69 1216 1221 10.1038/sj.ki.5000208 16609685